Impro Precision Industries (1286) H1 2025 earnings summary

Executive summary

• Revenue grew 2.0% year-over-year to HK$2,449.9M for 1H/2025, with strong performance in diversified industrials, high horsepower engine (+48.3%), and medical (+50.6%) segments, offset by declines in automotive, energy, and aerospace.

• Gross profit margin improved by 1.4 percentage points to 27.8%, and profit attributable to shareholders rose 13.7% to HK$346.3M; adjusted profit up 11.6% to HK$359.6M.

• Interim dividend maintained at HK$0.08 per share (total payout HK$151.0M), reflecting stable cash flow and business prospects.

• Operational resilience amid global trade tensions, with ongoing investments in Mexico campus expansion and global footprint strategies to hedge against cyclical and geopolitical risks.

• Basic EPS up 13.8% to 18.35 HK cents.

Financial highlights

• Adjusted EBITDA rose 3.0% year-over-year to HK$715.3M, with margin up to 29.2%.

• Gross profit increased 7.4% to HK$681.5M; gross margin improved to 27.8% from 26.4%.

• Net cash from operating activities increased 11.5% to HK$555.3M; free cash inflow from operations down 25.5% to HK$116.6M.

• Market capitalization increased 51.3% to HK$5,567.5M; total equity up 10.9% to HK$5,262.2M.

• Adjusted basic EPS increased 11.7% to 19.10 HK cents.

Outlook and guidance

• Full-year 2025 sales growth forecast maintained at mid- to high-single digits, with acceleration expected in 2H/2025.

• High horsepower engine and medical end-markets expected to drive growth; recovery anticipated in aerospace and energy in H2 2025.

• Capital expenditures in Mexico to remain high, with HK$600M budgeted for 2025 to support capacity expansion.

• Ample liquidity with ~HK$2.12B undrawn banking facilities to support ongoing strategies.